Dr. Millett is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1514 Jefferson Hwy
New Orleans, LA 70121Phone+1 504-842-3208
Education & Training
University of Cincinnati College of MedicineClass of 2016
Certifications & Licensure
LA State Medical License 2023 - 2024
DC State Medical License 2016 - 2020
VA State Medical License 2016 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2022 Nov 01
Roles: Contact
Publications & Presentations
PubMed
- 17 citationsAntibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.Rajesh M Valanparambil, Jennifer Carlisle, Susanne L Linderman, Akil Akthar, Ralph Linwood Millett
Journal of Clinical Oncology. 2022-11-20 - 9 citationsNeoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma: future outlook.Ibrahim Halil Sahin, Lana Khalil, Ralph Millett, Ahmed Kaseb
Chinese Clinical Oncology. 2021-01-11 - 12 citationsDirected Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.Ralph L. Millett, Jacob Elkon, Imad A. Tabbara
Anticancer Research. 2018-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
